Sudden Cardiac Death AND ICD CRT Therapy

The answer first

Sudden cardiac death (SCD) is unexpected circulatory collapse from a cardiac cause within one hour of symptom onset or unwitnessed death within 24 hours of last being seen alive, and the great majority are due to ventricular tachyarrhythmias complicating structural heart disease. The physician's job is not to memorise the surface of every trial, but to recognise who is at risk, decide who benefits from a device, and manage the device — and its complications — across the patient's life. ^[1]

A defensible exam answer rests on four pillars: ^[1]

1. Define the substrate and the risk window. Roughly 80 percent of SCD occurs in patients with ischaemic or non-ischaemic systolic heart failure, 10 to 15 percent in inherited cardiomyopathy and channelopathy, and the remainder in structurally normal hearts (idiopathic VF, early repolarisation, drug-induced torsades). The single best predictor in adults is left ventricular ejection fraction under 35 percent; the period immediately after myocardial infarction is paradoxically high-risk but device benefit lags — wait at least 40 days post-MI and 90 days after revascularisation before primary-prevention implantation.
2. Match the device to the indication. Primary-prevention ICDs reduce all-cause mortality in systolic heart failure (MADIT-II, SCD-HeFT); secondary-prevention ICDs save lives after cardiac arrest or spontaneous sustained VT (AVID). Add cardiac resynchronisation therapy (CRT) when QRS is broad (≥ 130 ms, typically left bundle branch block) and the patient remains symptomatic despite optimal medical therapy (COMPANION, CARE-HF). ^{[2] [3]}
3. Optimise guideline-directed medical therapy first and always. An ICD is a safety net, not a treatment — beta-blockers, mineralocorticoid antagonists, ACE inhibitors or ARB/ARNI, SGLT2 inhibitors and, where appropriate, statins reduce arrhythmia burden and mortality independently of the device. In DANISH, primary-prevention ICD did not improve survival in well-treated non-ischaemic cardiomyopathy, underscoring that modern drugs have eroded the marginal benefit of a device in this subgroup. ^[11]
4. Manage the device as a lifelong therapy with specific failure modes. Inappropriate and appropriate shocks, lead failure, device infection, electrical storm, psychological morbidity, driving restriction, and end-of-life deactivation are all predictable — each needs an explicit plan documented at implant and revisited at every review. ^[6]

DWE high-yield: "Forty and ninety." Wait 40 days after myocardial infarction and 90 days after revascularisation (or diagnosis of non-ischaemic cardiomyopathy on guideline therapy) before a primary-prevention ICD — the arrhythmia substrate may remodel and the survival benefit is not seen in the early window. For CRT, the threshold is QRS ≥ 130 ms with left bundle branch block morphology and LVEF ≤ 35 percent despite at least three months of optimal medical therapy. ^{[1] [4]}

References12ShowHide

1. [1]Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction N Engl J Med, 2002.PMID 11907286
2. [2]Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure N Engl J Med, 2005.PMID 15659722
3. [3]The Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias N Engl J Med, 1997.PMID 9411221
4. [4]Bristow MR, Saxon LA, Boehmer J, et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure N Engl J Med, 2004.PMID 15152059
5. [5]Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure N Engl J Med, 2005.PMID 15753115
6. [6]Kuck KH, Schaumann A, Eckardt L, et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial Lancet, 2010.PMID 20109864
7. [7]O'Mahony C, Jichi F, Pavlou M, et al. A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD) Eur Heart J, 2014.PMID 24126876
8. [8]Elliott PM, Anastasakis A, Borger MA, et al. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC) Eur Heart J, 2014.PMID 25173338
9. [9]Corrado D, van Tintelen JP, McKenna WJ, et al. Arrhythmogenic right ventricular cardiomyopathy: evaluation of the current diagnostic criteria and differential diagnosis Eur Heart J, 2020.PMID 31637441
10. [10]Priori SG, Schwartz PJ, Napolitano C, et al. Risk stratification in the long-QT syndrome N Engl J Med, 2003.PMID 12736279
11. [11]Køber L, Thune JJ, Nielsen JC, et al. Defibrillator Implantation in Patients with Nonischemic Systolic Heart Failure N Engl J Med, 2016.PMID 27571011
12. [12]Priori SG, Wilde AA, Horie M, et al. HRS/EHRA/APHRS expert consensus statement on the diagnosis and management of patients with inherited primary arrhythmia syndromes: document endorsed by HRS, EHRA, and APHRS in May 2013 and by ACCF, AHA, PACES, and AEPC in June 2013 Heart Rhythm, 2013.PMID 24011539